← All trials
NCT05114486
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- Nov 10, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 139
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eyenovia Inc.Lead sponsor
- Eyenovia Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.